Adjuvant therapy for gastric cancer: What have we learned since INT0116?

doi:10.3748/wjg.v21.i13.3850

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6633)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

472

WORD

278

HTML

3146

Tables (1-3)

110

Sum=4006

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1003

Download

1624

Sum=2627

Apr 7, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Apr 7, 2015; 21(13): 3850-3859
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3850

Table 3 Randomized clinical trials comparing perioperative chemotherapy vs observation

Study	Treatment	n	D	DFS	OS	Toxicities G3-G4
MAGIC[28]	ECF vs observation	503	D1-2	0.66 (0.53-0.81)^a	0.75 (0.60-0.93)^a	Leuco 27.8%, N 12.3%
ACCORD-07[30]	CF vs observation	224	NR	0.65 (0.48-0.89)^a	0.69 (0.50-0.95)^a	Leuco 20.2%, N 9.2%

^aP < 0.05, perioperative chemotherapy vs observation. D: Lymphadenectomy; DFS: Disease-free survival; OS: Overall survival; XELOX: Capecitabine + Oxaliplatin; N: Nausea; Leuco: Leucopenia; NR: Not reported.

Citation: Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: What have we learned since INT0116? World J Gastroenterol 2015; 21(13): 3850-3859
URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3850.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3850